title: Changes in gastrin and serum pepsinogens in monitoring of Helicobacter pylori response to therapy.
abstract: The aims of this study in 50 patients with H. pylori infection and duodenal ulcer were to examine the effect of eradication therapy on the serum levels of gastrin, pepsinogen I, and pepsinogen II and to investigate whether monitoring of the serum changes in these peptides after treatment could predict patient outcome. H. pylori status was assessed at entry and one and six months after therapy by culturing and microscopic analysis of the gastric mucosa and by [14C]urea breath test. Significant decreases were observed in the serum levels of gastrin (-11.4 +/- 3%), pepsinogen I (-28.9 +/- 4%), and pepsinogen II (-40.4 +/- 3%) in the 45 patients whose infection was eradicated, but not in the patients without eradication. Serum values of these peptides were unchanged in an additional group of 10 patients that only received omeprazol, none of whom had H. pylori eradicated. The best cutoff point of the percentage of each peptide to predict patient outcome was 10% for gastrin and pepsinogen I, and 15% for pepsinogen II. A pepsinogen II decrease > 15% resulted in the best marker of H. pylori clearance, accurately identifying patient outcome 86.6% of the time, whereas the diagnostic accuracy of gastrin and pepsinogen I was 61.7% and 76.6%, respectively. Significant correlations were found between the bacterial load assessed by histology with the serum concentrations of pepsinogen I and II and with the urease activity as measured by the amount of 14CO2 excreted. In conclusion, eradication of H. pylori infection is followed by a significant drop in serum levels of gastrin, pepsinogen I, and pepsinogen II. Changes in the latter are the most uniform and may be used as an indirect tool to predict treatment outcome.
authors.affiliation: Department of Nuclear Medicine, Clínica Puerta de Hierro, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Pérez-Paramo
authors.forename: A
authors.initials: A
authors.lastname: Albillos
authors.forename: J L
authors.initials: JL
authors.lastname: Calleja
authors.forename: C
authors.initials: C
authors.lastname: Salas
authors.forename: M C
authors.initials: MC
authors.lastname: Marín
authors.forename: M L
authors.initials: ML
authors.lastname: Marcos
authors.forename: G
authors.initials: G
authors.lastname: Cacho
authors.forename: P
authors.initials: P
authors.lastname: Escartín
authors.forename: J
authors.initials: J
authors.lastname: Ortiz-Berrocal
mesh_terms: D000328:Adult; D000368:Aged; D001944:Breath Tests; D004381:Duodenal Ulcer / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D005755:Gastrins / Q000097:blood*; D005756:Gastritis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D010435:Pepsinogens / Q000097:blood*
chemical_list: D005755:Gastrins; D010435:Pepsinogens